Digest Network Come funziona
Network
/
Società
Ge
Non verificato

Genmab A/S

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

41 comunicati stampa

Guarda tutti i comunicati
28/10/2026
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
Web e Social Network
Industria
Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
26/10/2026
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Web e Social Network
Industria
Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
25/10/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Fiere
Eventi
Industria
Web e Social Network
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
24/10/2026
Multimedialità
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Industria
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
23/10/2026
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Web e Social Network
Industria
Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
05/10/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
03/10/2026
Industria
Oncologia
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
06/07/2026
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Industria
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
29/06/2026
Cardiologia
Terza età
Biotecnologia
Farmaceutica
Oncologia
Salute
Vetrine/Shopping
Medicina - Varie
Eventi
Industria
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
13/06/2026
Cardiologia
Terza età
Biotecnologia
Farmaceutica
Oncologia
Salute
Vetrine/Shopping
Medicina - Varie
Eventi
Industria
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0